Kerman University of Medical Sciences Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2007
NCT04340128
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of pharmaceutics, Faculty of pharmacy, Kerman University of medical sciences | Kerman University of Medical Sciences

Active Ingredients

Drugs in Phase 3 Trials (1)

meglumine antimoniate (1 trial)

Drugs in Other Trials (2)

vitamin e (1 trial)

zinc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3